Spex

DGAP-News: Mister Spex SE: CFO Sebastian Dehnen leaves Mister Spex

Retrieved on: 
Mittwoch, Juni 15, 2022
Time, Spex, IPO, Saskatchewan River Sturgeon Management Board, Technology, Security (finance), Online shopping

"Sebastian has contributed significantly to the successful IPO of Mister Spex and prepared the company for the requirements of the capital market.

Key Points: 
  • "Sebastian has contributed significantly to the successful IPO of Mister Spex and prepared the company for the requirements of the capital market.
  • Sebastian Dehnen: "My time at Mister Spex has been marked by many exciting and successful events over the past years.
  • I will of course continue to follow the successful development of Mister Spex and remain a loyal customer."
  • Founded in 2007, Mister Spex SE (together with its subsidiaries, "Mister Spex") is a multi-award-winning company that has become the leading digitally-driven omni-channel optician in Europe.

Syed Jafry Joins Antylia Scientific Board of Directors

Retrieved on: 
Montag, April 25, 2022
Percussion section, Board, EMEA, General Electric, Zimmer Biomet, Water, Executive, Research, Plastic, Life, Science, Board of directors, Cole-Parmer, CAGR, Army Science Board, Goal, GM, GE, Growth, SVP, Thermo Fisher Scientific, Director, TMO, Solution, SRL Diagnostics, Industry, GTCR, Emerging market, Fine chemical, Management, Elective surgery, Spex, Asia-Pacific

VERNON HILLS, Ill., April 25, 2022 /PRNewswire/ -- Antylia Scientific, a global leader of Molecular Diagnostic Reagents and Specialty Chemicals, Water and Air Quality Testing Equipment and Consumables, and Laboratory Products for the pharma, healthcare and environmental markets, announced today that Syed Jafry has joined its Board of Directors. Antylia is a portfolio company of GTCR, a leading private equity firm.

Key Points: 
  • VERNON HILLS, Ill., April 25, 2022 /PRNewswire/ --Antylia Scientific, a global leader of Molecular Diagnostic Reagents and Specialty Chemicals, Water and Air Quality Testing Equipment and Consumables, and Laboratory Products for the pharma, healthcare and environmental markets, announced today that Syed Jafry has joined its Board of Directors.
  • Mr. Jafry also serves on the Board of Directors of Zimmer Biomet, a global leader in orthopedics.
  • "We are excited and honored to have Syed join our Board of Directors," said Bernd Brust, Antylia's Executive Chairman of the Board.
  • Mr. Jafry commented: "I am truly honored to join the Board of Antylia Scientific and to partner with the GTCR team.

DGAP-News: Mister Spex SE continues its omnichannel success story and achieves 18% revenue growth in 2021

Retrieved on: 
Freitag, April 1, 2022
EBITDA, MRX, Investment, Marketing, Growth, Annual report, Saskatchewan River Sturgeon Management Board, Environment, Travel, Intention, Spex, COVID-19, EUR, Awareness, Retail, International

"Despite the challenging environment, we again managed to grow stronger than the market", says Sebastian Dehnen, Chief Financial Officer and Member of the Management Board of Mister Spex SE.

Key Points: 
  • "Despite the challenging environment, we again managed to grow stronger than the market", says Sebastian Dehnen, Chief Financial Officer and Member of the Management Board of Mister Spex SE.
  • The revenue growth performance for 2021 was in line with the adjusted expectations of 17-19% announced on November 1st 2021.
  • Mister Spex is uniquely positioned to attract these customers with a market leading omnichannel approach and a wide wide range of products.
  • The annual report and further information for analysts and investors are available on the Mister Spex Investor Relations website .

DGAP-News: Mister Spex SE continues double-digit growth in third quarter of 2021

Retrieved on: 
Mittwoch, November 24, 2021
Coronavirus, Saskatchewan River Sturgeon Management Board, EBITDA, IKEA, IPO, MRX, Spex, Marketing, Intention, Lens (anatomy), Travel, Growth, Retail

The contact lens revenues benefited from Mister Spex' leading price-value proposition in many markets.

Key Points: 
  • The contact lens revenues benefited from Mister Spex' leading price-value proposition in many markets.
  • Compared to the third quarter of 2019, Mister Spex grew strongly by 35%.
  • In addition to expanding its retail network, Mister Spex has recently also been able to further expand its product range.
  • The quarterly report and the results presentation for analysts and investors are available on the Mister Spex Investor Relations website .

DGAP-News: Mister Spex SE plans Initial Public Offering

Retrieved on: 
Montag, Juni 14, 2021
Magazines, E-commerce, Marketing, Omnichannel, Spex, Periodicals, Mass media

Existing shareholders are expected to provide shares to cover potential over-allotments in the amount of c.15% of the base offering.

Key Points: 
  • Existing shareholders are expected to provide shares to cover potential over-allotments in the amount of c.15% of the base offering.
  • Mister Spex is the leading digitally native omnichannel optician in Europe, a fragmented and growing market.
  • This is clear evidence that our strategy works," says Dr Sebastian Dehnen, Chief Financial Officer of Mister Spex SE.
  • Founded in 2007, Mister Spex SE (together with its subsidiaries, "Mister Spex") is a multi-award-winning company that has become the leading digitally native omnichannel optician in Europe.

Reflow Medical Introduces the Spex™ LP, the Lowest Profile Shapeable Reinforced Support Catheter

Retrieved on: 
Donnerstag, Januar 14, 2021
Health, Surgery, Cardiology, Medical devices, Magazines, Reflow soldering, Soldering, Spex, Catheter, Periodicals

Reflow Medical, Inc., a California-based medical device company, introduces the Reflow Spex LP (Low Profile) 0.014 and 0.018-inch reinforced support catheters.

Key Points: 
  • Reflow Medical, Inc., a California-based medical device company, introduces the Reflow Spex LP (Low Profile) 0.014 and 0.018-inch reinforced support catheters.
  • The new Spex LP is engineered to provide the lowest profile tip for accessing and crossing the tightest and most complex lesions with a supportive system.
  • The Spex LP can be combined with the Reflow Spex 35 for more robust support.
  • View the full release here: https://www.businesswire.com/news/home/20210114005627/en/
    Reflow Spex LP (Low Profile) shapeable catheter is engineered to provide the lowest profile tip.

Spherix Issues Letter to Shareholders

Retrieved on: 
Freitag, Februar 14, 2020
Spex

NEW YORK, Feb. 14, 2020 /PRNewswire/ --Spherix Incorporated (NASDAQ: SPEX), a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders:

Key Points: 
  • NEW YORK, Feb. 14, 2020 /PRNewswire/ --Spherix Incorporated (NASDAQ: SPEX), a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders:
    One of the most important responsibilities of a public company CEO is a commitment to frequent and clear communication with shareholders.
  • Moving forward, we are committed to providing our shareholders with substantive information on these pioneering treatments, starting with our pancreatic cancer drug, DHA-dFdC.
  • All of this technology has been licensed to Spherix for commercial development and we could not be more enthusiastic about the potential to both meaningfully help patients and reward shareholders.
  • We look forward to keeping our shareholders apprised of our significant milestones as well as any potential setbacks along the way.

Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky

Retrieved on: 
Mittwoch, September 11, 2019
Proteasome inhibitor, Spex

NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor.

Key Points: 
  • NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor.
  • Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement for commercial development.
  • "Early research indicates great potential for the University of Kentucky's anticancer drug G4-1.
  • The published data is extremely encouraging, especially the drug's benefits over already-approved drugs," stated Mr. Anthony Hayes, CEO of Spherix.

Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board

Retrieved on: 
Montag, Oktober 29, 2018
Qureshi, Spex

NEW YORK, Oct. 29, 2018 /PRNewswire/ --Spherix Incorporated (Nasdaq: SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area.

Key Points: 
  • NEW YORK, Oct. 29, 2018 /PRNewswire/ --Spherix Incorporated (Nasdaq: SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area.
  • Dr. Rana Quraishi is the Director of New Ventures, at UM Ventures University of Maryland, Baltimore.
  • Dr. Quraishi has a Ph.D. in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an M.S.
  • Dr. Quraishi has spent much of her career working in life science directed finance, investment and consulting organizations.

SPEX Introduces Breakthrough Augmented Reality Headset Platform Designed to Provide Enhanced Vision in Precision Tasks

Retrieved on: 
Donnerstag, Mai 31, 2018
User interface techniques, Human–computer interaction, Augmented reality, Marketing, Virtual reality, Spex, Multimodal interaction, Mixed reality

SANTA CLARA, Calif., May 31, 2018 /PRNewswire/ --SPEX ( https://spex-ar.com/ ), a new division of eSight Corporation , is introducing its first augmented reality (AR) headset platform providing enhanced vision to commercial, industrial and medical applications with the need for precision vision without overwriting or obstructing users' natural vision.

Key Points: 
  • SANTA CLARA, Calif., May 31, 2018 /PRNewswire/ --SPEX ( https://spex-ar.com/ ), a new division of eSight Corporation , is introducing its first augmented reality (AR) headset platform providing enhanced vision to commercial, industrial and medical applications with the need for precision vision without overwriting or obstructing users' natural vision.
  • SPEX accomplishes this without overwriting or obstructing natural vision, allowing full situational awareness, higher work accuracy and greater safety.
  • "SPEX is a proven hardware and software platform that enables application developers to rapidly deliver high-quality, mobile, mission critical applications."
  • Mixed reality objects created for the SPEX platform maintain contrast and are viewable under any lighting conditions.